PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Metzeler, K.H.* ; Heilmeier, B.* ; Edmaier, K.E.* ; Rawat, V.P.S.* ; Dufour, A.* ; Döhner, K.* ; Feuring-Buske, M.* ; Braess, J. ; Spiekermann, K. ; Büchner, T.* ; Sauerland, M.C.* ; Döhner, H.* ; Hiddemann, W. ; Bohlander, S.K. ; Schlenk, R.F.* ; Bullinger, L.* ; Buske, C.*

High expression of Lymphoid Enhancer-binding Factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia.

Blood 120, 2118-2126 (2012)
Publ. Version/Full Text Volltext DOI PMC
Closed
Open Access Green as soon as Postprint is submitted to ZB.
Lymphoid enhancer-binding factor-1 (LEF1) is a key transcription factor of Wnt signaling. We recently showed that aberrant LEF1 expression induces acute myeloid leukemia (AML) in mice, and found high LEF1 expression in a subset of cytogenetically normal AML (CN-AML) patients. Whether LEF1 expression associates with clinical and molecular patient characteristics and treatment outcomes remained unknown. We therefore studied LEF1 expression in 210 adults with CN-AML treated on German AML Cooperative Group trials using microarrays. High LEF1 expression (LEF1(high)) associated with significantly better relapse-free survival (RFS; P < .001), overall survival (OS; P < .001), and event-free survival (EFS; P < .001). In multivariable analyses adjusting for established prognosticators, LEF1(high) status remained associated with prolonged RFS (P = .007), OS (P = .01), and EFS (P = .003). In an independent validation cohort of 196 CN-AML patients provided by the German-Austrian AML Study Group, LEF1(high) patients had significantly longer OS (P = .02) and EFS (P = .04). We validated the prognostic relevance of LEF1 expression by quantitative PCR, thereby providing a clinically applicable platform to incorporate this marker into future risk-stratification systems for CN-AML. Gene-expression profiling and immunophenotyping revealed up-regulation of lymphopoiesis-related genes and lymphoid cell-surface antigens in LEF1(high) patients. In summary, we provide evidence that high LEF1 expression is a novel favorable prognostic marker in CN-AML. (Blood. 2012; 120(10):2118-2126)
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
9.898
2.393
42
58
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Acute Lymphoblastic-Leukemia; Stem-Cell Transplantation; High-Dose Cytarabine; Normal Karyotype AMLl; Gene-Expression; Myelodysplastic Syndromes; Translocation Products; Prolonged Maintenance; Signaling Pathway; Adult Patients
Language english
Publication Year 2012
HGF-reported in Year 2012
ISSN (print) / ISBN 0006-4971
e-ISSN 1528-0020
Journal Blood
Quellenangaben Volume: 120, Issue: 10, Pages: 2118-2126 Article Number: , Supplement: ,
Publisher American Society of Hematology
Reviewing status Peer reviewed
Institute(s) CCG Pathogenesis of Acute Myeloid Leukemia (KKG-KPL)
POF-Topic(s) 30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Research field(s) Immune Response and Infection
PSP Element(s) G-521000-001
PubMed ID 22815426
DOI 10.1182/blood-2012-02-411827
WOS ID WOS:000309043700022
Scopus ID 84866158583
Erfassungsdatum 2012-10-26
[➜Report correction]